Addex appoints Dr Bharatt Chowrira CEO
This article was originally published in Scrip
Addex Pharmaceuticals has appointed Dr Bharatt Chowrira CEO, and dissolved the transition committee led by recently appointed vice-chairman Vincent Lawton, which was set up as an interim measure following the unexpected departure of former CEO Dr Vincent Mutel in June 2011 (scripintelligence.com, 3 June 2011). Dr Chowrira joins Addex from Nektar Therapeutics where he served as senior vice-president and COO, and he was previously executive director of worldwide licensing & external research at Merck & Co.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.